2 research outputs found
Synthesis and Feasibility Evaluation of a new Trastuzumab Conjugate Integrated with Paclitaxel and 89Zr for Theranostic Application Against HER2āExpressing Breast Cancers
Abstract The preparation and inā
vitro evaluation of a theranostic conjugate composed of trastuzumab, paclitaxel (PTX), and deferoxamine (DFO)āchelated 89Zr have been reported. These comounds have potential applications against HER2 receptor positive breast cancers. We conjugated DFO and PTX to trastuzumab by exploiting simple conjugation chemistry. The conjugate (DFOātrastuzumabāPTX) showed excellent radiolabeling efficiency with 89Zr and the labeled conjugate had high inā
vitro stability in human serum. Furthermore, DFOātrastuzumabāPTX displayed comparable cytotoxicity with PTX and 89ZrāDFOātrastuzumabāPTX exhibited HER2 receptorāmediated binding on HER2āpositive MDAāMBā231 breast cancer cells. The results of our inā
vitro study indicate high potential of 89ZrāDFOātrastuzumabāPTX to be utilized in the theranostic application against HER2āpostive breast cancers